Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug21 | 1. Characterize the immune response after infection with SARS-CoV-2 Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of the study COVID-EP is to classify all the complications occurring after the diagnosis of pulmonary embolism in patients tested initially COVID-19 positive and negative by RT-PCR (on nasopharyngeal sample) during the peak of the pandemic in France (April 2020). The patients will be followed for 1 year in order to provide clinical and paraclinical data not yet published in the literature. In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed. The collected complications will then be compared between each of the 3 following groups: [PCR-COVID 19-Neg & Sero-COVID 19-Neg] versus [PCR-COVID 19-Neg & Sero-COVID 19-Pos] versus [PCR-COVID 19-Pos].
Description: PE complications : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: % of patients for each group presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 6 months after PE diagnosis. Time: 6 months after PE diagnosisDescription: PE complications : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: % of patients for each group and subgroup presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 12 months after PE diagnosis. Time: 12 months after PE diagnosisDescription: PE complications : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: % of patients in each group presenting the occurrence of each of the following events at each follow-up (3 months, 6 months and 12 months after PE diagnosis). Time: 3, 6 and 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC PE complication : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: % of occurrence of PE complications for each categories of treatments Time: 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC Bleeding complications: classification 1-2-3-5 according to BARC
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with occurrence of bleeding complications for each categories of treatments Time: 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with no occurrence of complications for each categories of treatments Time: 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: duration of Heparin treatment (number of day) Time: 12 months after PE diagnosisThe purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.
Description: % of anti-covid positive cells
Measure: Presence and quantification of CD4 / CD8 reactivity to COVID-19 epitopes in patient with positive and negative serological tests for covid-19 Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports